Mohammed, B., Al.Nuaimy, W. (2024). Immunohistochemical Expression of Galectin-3 in Thyroid Neoplasms and its Correlation with CD56. , 23(4), 405-412. doi: 10.52573/ipmj.2024.138871
Banan Burhan Mohammed; Wahda Mohammed Taib Al.Nuaimy. "Immunohistochemical Expression of Galectin-3 in Thyroid Neoplasms and its Correlation with CD56". , 23, 4, 2024, 405-412. doi: 10.52573/ipmj.2024.138871
Mohammed, B., Al.Nuaimy, W. (2024). 'Immunohistochemical Expression of Galectin-3 in Thyroid Neoplasms and its Correlation with CD56', , 23(4), pp. 405-412. doi: 10.52573/ipmj.2024.138871
Mohammed, B., Al.Nuaimy, W. Immunohistochemical Expression of Galectin-3 in Thyroid Neoplasms and its Correlation with CD56. , 2024; 23(4): 405-412. doi: 10.52573/ipmj.2024.138871

Immunohistochemical Expression of Galectin-3 in Thyroid Neoplasms and its Correlation with CD56

Iraqi Postgraduate Medical Journal
Article 5, Volume 23, Issue 4, October 2024, Pages 405-412    PDF (496.28 K)
Document Type: Research Paper
DOI: 10.52573/ipmj.2024.138871
Authors
Banan Burhan Mohammed* 1; Wahda Mohammed Taib Al.Nuaimy2
1Pathology department,collage of medicine ,university of Mosul,Mosul,Iraq
2Pathology/college of medicine /university of Mosul
Abstract
Abstract
Background: The incidence of thyroid cancer has been increasing significantly since the mid-1990s.Some studies have revealed that in thyroid gland, the galectin-3 plays a role in the pathogenesis of well-differentiated carcinoma. For that, it is may be one of the markers that may help to assist in distinguishing thyroid neoplasms.
Objective : To detect the frequency of immunohistochemical expression and diagnostic value of Galectin-3 in different types of thyroid neoplasms.To correlate the expression of galectin-3 findings with immunoprofile data of CD56. To correlate the result of immunohistochemical expression of Galectin-3 with the age and gender of the sampled cases.
Patients and method: A retrospective case series study was intended in fifty surgically removed cases of primary thyroid neoplasm whose CD56 status had been tested by immunohistochemical technique. The galectin-3 protein was tested on formalin fixed paraffin embedded section by immunohistochemical method using Ab-1, isotype IgG1,clone 9C4 , Mouse Monoclonal Antibody .
Results: galectin-3 was positive in 52 % of the cases. Relation of galectin-3 with the histological type of neoplasm and malignant tumors versus benign was significant (P= 0.000152 , P=0.000712 respectively). The galectin-3 was expressed in most of non-follicular pattern (p =0.00001). In this study, 42% of the cases were galectin-3 positive/ CD56 negative and 38% of the cases were galectin-3 negative/CD56 positive, the association of galectin-3 with CD56, was significant (P=0.000023).
Conclusion: Galectin-3 immune stain marker considered as a useful marker in differentiating malignant tumors with non-follicular pattern, especially papillary thyroid carcinoma, from a benign tumors. Significant association was found between Galectin-3 and CD56. Galectin-3 can be used as a positive marker while the CD65 is a negative marker for diagnosis of thyroid carcinoma.
Keywords
Key words: thyroid cancer; galectin-3; papillary carcinoma; CD56
References
  1. Prete A, Borges de Souza P, Thyroid Censi S, Muzza M, Nucci N, Sponziello M. Update on fundamental mechanisms of Cancer. Front Endocrinol (Lausanne). 2020;11:1-10. doi:10.3389/fendo.2020.00102.
  2. Aliyev E, Ladra-González MJ, Sánchez-Ares M, Nallib IA, Piso-Neira M, Rodríguez-Carnero G, et al. Thyroid papillary microtumor : Validation of the (Updated) porto proposal assessing sex hormone receptor expression and mutational BRAF gene Status. Am J Surg Pathol. 2020; 44:1161-72.
  3. Arrangoiz R, Cordera F, Caba D, Moreno E, Luque-De-Leon E, Muñoz M. Thyroid cancer keywords. Int J Otolaryngol Head Neck Surg. 2019;8:217-70.
  4. Zargari N, Mokhtari M. Evaluation of Diagnostic Utility of immunohistochemistry markers of TROP-2 and HBME-1 in the diagnosis of thyroid carcinoma. Eur Thyroid J. 2019;8:1-6. doi:10.1159/000494430
  5. De Rose F, Braeuer M, Braesch-Andersen S, Otto AM, Steiger K, Reder S, et al. Galectin-3 targeting in thyroid orthotopic tumors opens new ways to characterize thyroid cancer. J Nucl Med. 2019;60:770-76. doi:10.2967/jnumed.118.219105
  6. Pyo JS, Kim DH, Yang J. Diagnostic value of CD56 immunohistochemistry in thyroid lesions. Int J Biol Markers. 2018;33:161-67.
  7. Tang W, Huang C, Tang C, Xu J, Wang H. Galectin-3 may serve as a potential marker for diagnosis and prognosis in papillary thyroid carcinoma: A meta-analysis. Onco Targets Ther. 2016;9:455- 60. doi:10.2147/OTT.S94514
  8. Albi E, Curcio F, Lazzarini A, Floridi A, Cataldi S, Lazzarini R , et al. How Micro gravity changes galectin-3 in thyroid follicles. Biomed Res Int. 2014;2014:1-5.
  9. Abdullah MI, Junit SM, Ng KL, Jayapalan JJ, Karikalan B, Hashim OH. Papillary thyroid cancer: Genetic alterations and molecular biomarker investigations. Int J Med Sci. 2019;16:450- 60. doi:10.7150/ijms.29935
  10. Parsa AA, Gharib H. Update on thyroid nodule management. US Endocrinol. 2019;15:32- 8. doi:10.17925/USE.2019.15.1.32.
  11. Tastekin E, Keskin E , Can  N, Canberk  S,  Mut  A, Erdogan E  , et al. CD56, CD57, HBME1, CK19, Galectin-3 and p63 immunohistochemical stains in differentiating diagnosis of thyroid benign/malign lesions and NIFTP . Pol J Pathol . 2019;70:286-94. doi: 10.5114/pjp.
  12. Borkar PV, Gowrinath K, Sandeep K. Intensity and grading of galectin-3 expression as a sole marker to differentiate benign and malignant thyroid neoplasms. Nat. J of Lab Med. 2019;8:1-4. doi:10.7860/ NJLM/ 2019/ 40370.
  13. Ozcinar B, Es B, Ertugrul B, Ha E. Galectin-3 expression in thyroid papillary cancer. Austin J Surg . 2019; 6:1-5.
  14. Weinberger PM, Adam BL, Gourin CG, Moretz WH, Bollag RJ, Wag BY, et al. Association of nuclear, cytoplasmic expression of galectin-3 with β-catenin/Wnt-pathway activation in thyroid carcinoma. Arch Otolaryngol - Head Neck Surg. 2007;133:503-10.
  15. Bartolazzi A, Sciacchitano S, D’Alessandria C. Galectin-3: The impact on the clinical management of patients with thyroid nodules and future perspectives. Int J Mol Sci. 2018;19. doi:10.3390/ijms19020445
  16. Chiu CG, Strugnell SS, Griffith OL,Jones SJM ,Gown AM, Walker B, et al. Diagnostic utility of galectin-3 in thyroid cancer. Am J Pathol. 2010;176:2067-81.
  17. Dunderović D, Lipkovski JM, Boričic I, Soldatović I,  Božic V,  Dubravka Cvejić D, et al . Defining the value of CD56, CK19, galectin 3 and HBME-1 in diagnosis of follicular cell derived lesions of thyroid with systematic review of literature. Diagn Pathol. 2015;10. doi:10.1186/s13000-015-0428-4
  18. Elkateb MI, Ahmed M, Mohammed S, Mostafa M. Evaluation of thyroid nodules using thyroid peroxidase and galectin-3:an immunohistochemical study. Zagazig Univ Med J. 2013;19:1-8. doi:10.21608/zumj.2013.4263
  19. Sumana BS, Shashidhar S, Shivarudrappa AS. Galectin-3 immunohistochemical expression in thyroid neoplasms. J Clin Diagnostic Res. 2015;9:EC07-EC11.
  20. Harazono Y, Kho DH, Balan V, et al. Galectin-3 leads to attenuation of apoptosis through Bax heterodimerization in human thyroid carcinoma cells. Oncotarget.2014;5:9992-10001. doi:10.18632/oncotarget.2486
  21. Al-Jubouri RSM ,Mohamed BJ ,Naji RZ . Detection of some biomarkers in Iraqi patients with thyroid carcinoma. Journal of Pharmacy and Biological Sciences (IOSR-JPBS). 2017;12:34-9. e-ISSN:2278-3008, p-ISSN:2319-7676.
  22. Mandal AP, Saha R, Mitra S. Immunohistochemical expression of galectin-3 and cytokeratin 19 in the Spectrum of Thyroid Neoplasms J Clin Diagnostic Res. 2021;15:19-23.
  23. Ahmed AJ. Immunohistochemical expression of CD56 in thyroid neoplasms in Nineveh province .A thesis submitted to the Scientific Council of Pathology in partial fulfillment of the requirement for the degree of fellowship of the Iraqi Board for Medical Specialization in Pathology/Histopathology,2020
  24. Dhal A, Agrawal S, Mishra DP.Evaluation of galectin-3 expression in non-neoplastic and neoplastic lesions of thyroid.JMSCR 2021;9: 61-67.
  25. Bozdogan Arpaci R. Thyroid tumors with encapsulated follicular pattern : A diagnostıc dilemma. Adv Cytol Pathol. 2017;2:90-7.
 

 

Statistics
Article View: 265
PDF Download: 114


Journal Management System. Powered by iJournalPro.com